Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10171777 | 0.95 | TRPA1 (0.65) | TRPA1MAPT | |
| SCHEMBL10171371 | 0.95 | TRPA1 (0.79) | TRPA1MAPT | |
| SCHEMBL612181 | 0.89 | TRPA1 (0.90) | TRPA1MAPT | |
| SCHEMBL15746154 | 0.87 | TRPA1 (0.84) | TRPA1MAPT | |
| SCHEMBL10171043 | 0.87 | TRPA1 (0.67) | TRPA1MAPT | |
| SCHEMBL2449784 | 0.85 | TRPA1 (0.58) | TRPA1MAPT | |
| SCHEMBL612953 | 0.85 | TRPA1 (0.65) | TRPA1MAPT | |
| SCHEMBL609712 | 0.84 | TRPA1 (0.66) | TRPA1MAPT | |
| SCHEMBL612387 | 0.84 | TRPA1 (0.73) | TRPA1MAPT | |
| SCHEMBL609868 | 0.84 | TRPA1 (1.00) | TRPA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120316136-A1 | TREATMENT OF RESPIRATORY DISORDERS USING TRPA1 ANTAGONISTS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120041004-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316136-A1 | TREATMENT OF RESPIRATORY DISORDERS USING TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885MAPT 2700/4885 |
| US-20120041004-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS | TRPA1, TRPV1, TRPC3 | TRPA1 1/4885MAPT 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.